Tezepelumab is a monoclonal antibody used primarily in the treatment of severe asthma. It works by targeting and inhibiting thymic stromal lymphopoietin (TSLP), a protein involved in the initiation and progression of airway inflammation. By blocking TSLP, tezepelumab helps reduce the frequency of asthma exacerbations and improves lung function, even in patients with low eosinophil levels who typically do not respond well to other biologic therapies. It is administered via subcutaneous injection and is indicated for use in adults and adolescents with severe, uncontrolled asthma as an add-on maintenance therapy. Its broad mechanism of action makes it effective across multiple asthma phenotypes, offering a valuable option for patients with limited treatment alternatives.